From Eligibility to Exploratory: Planning and Implementing Biomarker Testing for I-O
Join us from 11am-12pm.
April 27, 2016 - April 27, 2016 | 12:00 - 13:00 Add to Calendar
About This EventFoundations laid by fundamental cancer biology and immunology research have led to game-changing clinical breakthroughs in the field of Immuno-oncology. However, a deep understanding of the intricate workings of the anti-tumor immune response is required to truly harness and apply its power and is still a work in-progress. With mechanisms still partially veiled and hypotheses emerging from all angles, one thing is clear –Immuno-oncology is complex and these trials have brought new challenges to all corners of drug development, including clinical biomarker testing.
In this webinar, scientists from Q2 Solutions will highlight some of the particular challenges associated with the diverse clinical biomarker requirements of Immuno-oncology trials and specifically discuss how our laboratories have worked with Pharma clients to bring key research tools- anatomic pathology, flow cytometry, and genomics- into Immuno-oncology clinical trials. Our scientists will also address the potential development of companion diagnostics.
By attending this webinar you will:
- Learn about the challenges and critical success factors associated with implementing biomarker testing in Immuno-oncology trials
- Gain knowledge on considerations for biomarker defined Immuno-oncology clinical trials and the development of companion diagnostics
Linda Robbie, Ph.D.
Senior Director, Biomarkers and Global Translational Science Laboratory
Linda Robbie, Ph.D. is senior director of Q2 Solutions Global Translational Science Laboratory. In her role, she leads the development and validation of biomarker assays across a wide range of technologies, including immunoassay (single and multiplex), flow cytometry, cell based assays, targeted genomics and tandem mass spectrometry. Dr. Robbie participates in the Scientific Advisors network of Q2 Solutions, and has the responsibility of providing scientific oversight for biomarker strategy and assay development within the Q2 Solutions global laboratory network as well as serving as the scientific liaison for biomarkers with our customers.
Dr. Robbie has more than 25 years of experience with biomarker assay technologies, including 20 years in scientific leadership positions. She was instrumental in establishing the Q2 Solutions global assay development business from the ground up while leading a team of multi-disciplined subject matter experts working with state-of-the-art technologies. She has authored over 30 peer-reviewed publications and is the recipient of several research grants and awards.
Dr. Robbie earned a Bachelor’s degree in Biochemistry from Heriot-Watt University in Edinburgh and a Ph.D. from the Department of Medicine and Therapeutics at the University of Aberdeen in Scotland, UK before serving as a post-doctoral research fellow in Cardiovascular Science at Harvard Medical School in Boston, Massachusetts.
Radha Krishnan, MD
Chief Pathologist and Senior Medical Director
Radha Krishnan, M.D., is chief pathologist at Q2 Solutions, a Quintiles Quest Joint Venture. In this role, and in collaboration with the company’s chief scientific officer and chief operating officer, Dr. Krishnan defines the plan for global Anatomic Pathology (AP) service offerings, including instrumentation, technician and pathologists. Additionally, she serves as the scientific advisor for AP services, such as immunohistochemistry (IHC), In-Situ Hybridization (ISH) hematopathology and cytology. This includes the supervision of all assay validation, Pathologist and staff training, proficiency testing, the review and approval of related SOPs, and validations to ensure global harmonization of AP laboratory testing in accordance with applicable regulations governing clinical laboratories.
Dr. Krishnan has more than 22 years of post-specialization experience, with the last seven years in senior leadership roles within Quintiles and Q2 Solutions, including the senior medical director and head of AP for Europe and Asia. Prior to her work at Quintiles, Dr. Krishnan worked as a consultant Pathologist in tertiary referral hospitals and cancer centers and specialized in tumor pathology. Dr. Krishnan has also been in the academia as an Associate professor in Pathology in the Faculty of Medicine at the University Technology MARA in Malaysia, and a lecturer in Pathology at the International Medical University in Kuala Lumpur.
Dr. Krishnan obtained her Bachelor of Medicine, Bachelor of Surgery (M.B.B.S) and her Doctorate in Medicine (M.D., Pathology) from the University of Madras in India. She is also a Member of the International Academy of Cytology (MIAC).
Patrick Hurban, Ph.D.
Senior Director and Global Head, Genomic Development/Esoteric Assays
Patrick Hurban, Ph.D. is senior director and global head of Genomic Development/Esoteric Assays at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assays that target a smaller number of genes.
Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 15 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.
Alistair J. Watt, Ph.D.
Director, Translational Science Laboratory, Europe
Alistair Watt, Ph.D. is the Director of the Translational Science Laboratory (ADL) in Europe and is based in Edinburgh, Scotland. He has significant experience in the development of flow cytometry, ELISA and Molecular Biology assays for clinical trials.
Before joining Q2 Solutions, Dr. Watt was a Senior Post-Doctoral Fellow at the University of Edinburgh working on a European Union Framework 6 project to define the conditions necessary for controlled embryonic cell differentiation to multiple cell types. In this role, he mentored Ph.D. students and produced coursework and taught undergraduates.
From 2000-2003, Dr. Watt worked at the Medical College of Wisconsin, Milwaukee. He was awarded an American Heart Association Post –Doctoral fellowship to study the transcriptional control of heart development leading to a number of high profile publications.
Dr. Watt received his Ph.D. from the University of Edinburgh in 1999 for work on liver development as a model for tissue formation and differentiation.